LI

FarmsynthezMOEX LIFE Stock Report

Last reporting period 30 Dec, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

0.017

Micro

Exchange

MISX - Moscow Exchange

LIFE.ME Stock Analysis

LI

Avoid

Based on Eyestock quantitative analysis, LIFE.ME`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-51/100

Low score

Market cap $B

0.017

Dividend yield

Shares outstanding

301.01 B

Pharmsynthez PJSC engages in the research, development, manufacture, and distribution of pharmaceuticals. The firm focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The firm sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. The company has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Company’s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

View Section: Eyestock Rating